rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
8
|
pubmed:dateCreated |
2006-7-28
|
pubmed:abstractText |
The aim of the study was to determine the safety profile, pharmacokinetics and potential drug interactions of the angiogenesis inhibitor ABT-510 combined with gemcitabine-cisplatin chemotherapy in patients with solid tumors.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0923-7534
|
pubmed:author |
pubmed-author:CarrR ARA,
pubmed-author:EskensF A L MFA,
pubmed-author:GietemaJ AJA,
pubmed-author:GroenH J MHJ,
pubmed-author:HoekstraRR,
pubmed-author:HumerickhouseR ARA,
pubmed-author:KnightR ARA,
pubmed-author:LoosW JWJ,
pubmed-author:UgesD R ADR,
pubmed-author:de VosF Y F LFY,
pubmed-author:van der GaastAA
|
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1320-7
|
pubmed:dateRevised |
2008-6-5
|
pubmed:meshHeading |
pubmed-meshheading:16728485-Adult,
pubmed-meshheading:16728485-Aged,
pubmed-meshheading:16728485-Angiogenesis Inhibitors,
pubmed-meshheading:16728485-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16728485-Cisplatin,
pubmed-meshheading:16728485-Deoxycytidine,
pubmed-meshheading:16728485-Drug Interactions,
pubmed-meshheading:16728485-Female,
pubmed-meshheading:16728485-Humans,
pubmed-meshheading:16728485-Male,
pubmed-meshheading:16728485-Middle Aged,
pubmed-meshheading:16728485-Neoplasms,
pubmed-meshheading:16728485-Oligopeptides,
pubmed-meshheading:16728485-Thrombospondin 1
|
pubmed:year |
2006
|
pubmed:articleTitle |
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.
|
pubmed:affiliation |
Department of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands. j.a.gietema@int.umcg.nl
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|